Unresectable liver cancer: 1. Unresectable in the sense of surgery, including the patient's overall condition that cannot tolerate surgical trauma, intolerable liver function, insufficient future liver remnant (FLR), etc. (referred to as unresectable in surgery for short). 2. Technically resectable, but no better therapeutic effect can be achieved after resection than non-surgical treatment (refer
Conditions
Interventions
TACE:Vispearl Radiopaque Drug-eluting Microspheres for TACE
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 75 years old, no restriction on gender; 2.Patients with hepatocellular carcinoma diagnosed according to the clinical diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer" (2024 edition) or confirmed by pathological histology or cytology examination; 3. Had not received any treatment related to liver cancer in the past, including but not limited to systemic therapy, local treatment, liver cancer resection, etc.; 4.Patients with unresectable CNLC Ia-IIIa stage; 5.function classified as Child-Pugh A or B (7~8 points); 6.Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0~1; 7.According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), the patient has at least one measurable tumor lesion; 8.Participants who agree to take part in this clinical trial and voluntarily sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.The subject has previously received anti-treatment, such as: surgical resection, local treatment (interventional embolization chemotherapy, radiotherapy, ablation), systemic therapy, etc. 2.Patients with extrahepatic metastasis of hepatocellular carcinoma; 3.The lesion accounts for more than 70% of the liver volume; 4.Severe liver dysfunction (Child-Pugh Class C), including jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome; 5.Renal dysfunction: serum creatinine >176.8 µmol/L or creatinine clearance = 2, cachexia or multi-organ failure; 11.Known severe iodine contrast agent or embolic material allergy; 12.Patients with contraindications to systemic therapy drugs; 13.Pregnant/lactating women, or those planning to conceive; 14.Patients who are currently participating in other drug or device clinical trials, have not yet withdrawn, or have withdrawn for less than 1 month; 15.Persons without independent decision-making capacity or mental illness patients; 16.Researchers believe other patients unsuitable for participation in this clinical trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Conversion removal rate; | — |
Countries
China
Contacts
Public ContactXin Zheng
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed